Trial Profile
A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms GEM-CARBO
- 11 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 19 Mar 2014 Accruel to date is 14% according to UK Clinical Research Network record.
- 09 Mar 2009 Status changed from recruiting to active, no longer recruiting, according to United Kingdom Clinical Research Network.